Study identifier:D5090C00007
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I, Single-Centre, Randomised, Open-Label, Five-Way Cross-Over Formulation- and Food-Effect Study in Healthy Volunteers to Assess the Pharmacokinetics of AZD1386 after Single Doses of Two Oral Solid Formulations and an Oral Solution
pharmacokinetics
Phase 1
Yes
AZD1386
All
12
Interventional
20 Years - 45 Years
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1 fasting state | Drug: AZD1386 One single oral dose of 90mg (36mL of AZD1386 2.5mg/mL oral solution). |
Experimental: 2 fasting state | Drug: AZD1386 One single oral dose of 90mg (3 x 30mg AZD1386 capsules) |
Experimental: 3 non-fasting state | Drug: AZD1386 One single oral dose of 90mg (3 x 30mg AZD1386 capsules) |
Experimental: 4 fasting state | Drug: AZD1386 One single oral dose of 90mg (6 x 15mg AZD1386 tablets) |
Experimental: 5 non-fasting state | Drug: AZD1386 One single oral dose of 90mg (6 x 15mg AZD1386 tablets) |